Switch theme
Sign up to access all valuation multiples
Theraclion is a France-based company specializing in high-tech therapeutic ultrasound equipment. The product, Echopulse, helps in the treatment of breast fibroadenomas and benign thyroid nodules.
2004
29
Last FY Revenue $0.9M
Last FY EBITDA -$6.6M
$11.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Theraclion achieved revenue of $0.9M and an EBITDA of -$6.6M.
Theraclion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Theraclion valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.9M | XXX | XXX | XXX |
| Gross Profit | XXX | -$3.2M | XXX | XXX | XXX |
| Gross Margin | XXX | -346% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -710% | XXX | XXX | XXX |
| EBIT | XXX | -$7.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -820% | XXX | XXX | XXX |
| Net Profit | XXX | -$6.5M | XXX | XXX | XXX |
| Net Margin | XXX | -693% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Theraclion's stock price is EUR 0 (or $0).
Theraclion has current market cap of EUR 13.2M (or $14.9M), and EV of EUR 10.4M (or $11.6M).
See Theraclion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.6M | $14.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Theraclion has market cap of $14.9M and EV of $11.6M.
Theraclion's trades at 12.5x EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate Theraclion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Theraclion's P/E ratio is not available.
See valuation multiples for Theraclion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14.9M | XXX | $14.9M | XXX | XXX | XXX |
| EV (current) | $11.6M | XXX | $11.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 12.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -2.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTheraclion's revenue per employee in the last FY averaged $32K, while opex per employee averaged $0.2M for the same period.
Theraclion's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Theraclion's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Theraclion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -710% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $32K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 474% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Theraclion acquired XXX companies to date.
Last acquisition by Theraclion was XXXXXXXX, XXXXX XXXXX XXXXXX . Theraclion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Theraclion founded? | Theraclion was founded in 2004. |
| Where is Theraclion headquartered? | Theraclion is headquartered in France. |
| How many employees does Theraclion have? | As of today, Theraclion has 29 employees. |
| Is Theraclion publicy listed? | Yes, Theraclion is a public company listed on PAR. |
| What is the stock symbol of Theraclion? | Theraclion trades under ALTHE ticker. |
| When did Theraclion go public? | Theraclion went public in 2014. |
| Who are competitors of Theraclion? | Similar companies to Theraclion include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Theraclion? | Theraclion's current market cap is $14.9M |
| Is Theraclion profitable? | Yes, Theraclion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
